Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EXS74539 · 1 trial · 12 indications
| Arm | Type | Description |
|---|---|---|
| EXS74539 | EXPERIMENTAL | EXS74539 |
| Name | Type | Description |
|---|---|---|
| EXS74539 | DRUG | Oral administration |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of the following solid tumors: * SCLC * High grade neuroendocrine or small cell carcinomas of non-lung origin * Non-small cell lung cancer \[NSCLC\] * Prostat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EXS74539 is an investigational small molecule being studied for the treatment of select solid tumors, including small cell lung cancer, high grade neuroendocrine cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, renal carcinoma, head and neck squamous cell carcinoma, hepatic cancer, gastric cancer, and triple-negative breast cancer. It is currently in Phase 1 clinical development.
EXS74539 targets LSD1, an enzyme involved in epigenetic regulation. By inhibiting LSD1, the drug aims to alter gene expression in cancer cells. This target is being explored in the context of multiple solid tumor types, with the goal of developing a targeted therapeutic approach for patients with these malignancies.
EXS74539 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RXRX. The company is conducting a Phase 1 clinical trial to evaluate the safety and tolerability of this investigational drug in patients with select solid tumors.
EXS74539 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is a dose-determining study designed to evaluate the drug's safety, tolerability, and pharmacokinetics in participants with select solid tumors.
EXS74539 is being evaluated in a single Phase 1 clinical trial with the identifier NCT07517198. This trial, titled "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors," is currently recruiting participants in the United States. The study is uncontrolled, non-randomized, and open-label, with an enrollment target of 40 participants.
Yes, EXS74539 is also known as REC-4539. The clinical trial NCT07517198 refers to the drug as EXS74539 (REC-4539), indicating that both names are used interchangeably for the same investigational compound. This naming convention is common during drug development, where different codes may be assigned by the sponsor.